MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 10-02-2025
AngioDynamics EBITDA 2011-2026 | ANGO
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA AngioDynamics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -14.2 M | -165 M | -20.3 M | 878 K | -9.37 M | -143 M | 16 M | 42.9 M | 42.5 M | 32.5 M | 35.3 M | 39.3 M | 38.8 M | 22.6 M | 21.2 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 42.9 M | -165 M | -3.99 M |
Quarterly EBITDA AngioDynamics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.64 M | - | -7.38 M | -8.53 M | -6.31 M | - | -197 M | -9.56 M | 41.7 M | - | -4.19 M | -3.31 M | -5.64 M | -5.94 M | -400 K | -3.79 M | -1.1 M | -2.5 M | 554 K | -243 K | 1.46 M | 8.18 M | 1.46 M | 1.11 M | 4.38 M | 7.69 M | 4.38 M | 1.98 M | -530 K | 16.3 M | 5.92 M | 5.27 M | 5.93 M | 12.8 M | 5.93 M | 19.9 M | 9.72 M | 27.9 M | 9.72 M | 5.05 M | 7.32 M | 15.7 M | 8.29 M | 7.55 M | 9 M | 18.6 M | 9.94 M | 5.78 M | 7.31 M | 13.9 M | 7.38 M | 9.23 M | 7.27 M | 17.3 M | 3 M | 6.23 M | 5.85 M | 10.2 M | 5.85 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 41.7 M | -197 M | 2 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical instruments industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Luminex Corporation
LMNX
|
72.9 M | - | - | $ 1.75 B |  USA |
 |
Akers Biosciences, Inc.
AKER
|
-12.3 M | - | -9.52 % | $ 20.6 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
-11.8 M | $ 10.9 | 9.0 % | $ 26.4 M | USA |
 |
AtriCure
ATRC
|
2.64 M | $ 31.07 | -1.26 % | $ 1.48 B | USA |
 |
Atrion Corporation
ATRI
|
37.7 K | - | - | $ 810 M | USA |
 |
Isoray
ISR
|
-88.6 M | - | 0.03 % | $ 108 M | USA |
 |
The Cooper Companies
COO
|
1.06 B | $ 81.93 | -1.73 % | $ 16.3 B | USA |
 |
Alcon
ALC
|
580 M | $ 84.0 | 1.13 % | $ 40.4 B |  Schweiz |
 |
Antares Pharma, Inc.
ATRS
|
16.2 M | - | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
123 M | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
33.9 M | - | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
518 M | - | -0.05 % | $ 10.3 B | USA |
 |
Baxter International
BAX
|
673 M | $ 19.1 | 0.45 % | $ 9.8 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
60 M | - | -0.02 % | $ 16.3 B | USA |
 |
Glaukos Corporation
GKOS
|
-95 M | $ 115.62 | -1.86 % | $ 5.6 B | USA |
 |
Haemonetics Corporation
HAE
|
337 M | $ 64.55 | -1.59 % | $ 3.25 B | USA |
 |
iRhythm Technologies
IRTC
|
-36.7 M | $ 127.87 | 1.61 % | $ 4.09 B | USA |
 |
Predictive Oncology
POAI
|
-10.8 M | - | - | $ 31.1 M | USA |
 |
Harvard Bioscience
HBIO
|
3.37 M | $ 0.58 | 2.14 % | $ 24.6 M | USA |
 |
Becton, Dickinson and Company
BDX
|
5.04 B | $ 171.22 | -1.8 % | $ 49.3 B | USA |
 |
Repro Med Systems
KRMD
|
-9.4 M | $ 4.88 | 2.2 % | $ 223 M | USA |
 |
LeMaitre Vascular
LMAT
|
78.3 M | $ 106.91 | -0.87 % | $ 2.42 B | USA |
 |
Masimo Corporation
MASI
|
-164 M | $ 175.43 | 0.04 % | $ 9.35 B | USA |
 |
Microbot Medical
MBOT
|
-9.75 M | $ 2.47 | 3.28 % | $ 25.2 M |  Israel |
 |
BioLife Solutions
BLFS
|
-1.97 M | $ 20.59 | 2.06 % | $ 949 M | USA |
 |
Nephros
NEPH
|
-1.38 M | $ 3.92 | 1.29 % | $ 40.7 M | USA |
 |
electroCore
ECOR
|
-18.3 M | $ 7.9 | 3.81 % | $ 43.6 K | USA |
 |
Envista Holdings Corporation
NVST
|
332 M | $ 28.51 | -0.52 % | $ 4.79 B | USA |
 |
ResMed
RMD
|
1.16 B | $ 258.94 | 0.22 % | $ 37.8 B | USA |
 |
Pulse Biosciences
PLSE
|
-76.5 M | $ 18.29 | 1.89 % | $ 1.23 B | USA |
 |
Retractable Technologies
RVP
|
-13.5 M | $ 0.68 | -3.05 % | $ 20.4 M | USA |
 |
ICU Medical
ICUI
|
244 M | $ 142.18 | -0.34 % | $ 3.5 B | USA |
 |
InfuSystem Holdings
INFU
|
15 M | $ 9.57 | 4.25 % | $ 198 M | USA |
 |
Intuitive Surgical
ISRG
|
3.55 B | $ 501.88 | 0.9 % | $ 179 B | USA |
 |
Repligen Corporation
RGEN
|
116 M | $ 126.05 | 2.43 % | $ 7.02 M | USA |
 |
STERIS plc
STE
|
1.34 B | $ 244.67 | 0.62 % | $ 24.1 B | USA |
 |
Teleflex Incorporated
TFX
|
192 M | $ 119.41 | -2.24 % | $ 5.33 B | USA |
 |
Merit Medical Systems
MMSI
|
308 M | $ 74.53 | -0.43 % | $ 4.41 B | USA |
 |
Utah Medical Products
UTMD
|
17.4 M | $ 67.17 | 0.99 % | $ 244 M | USA |
 |
STAAR Surgical Company
STAA
|
-83.4 M | $ 19.17 | 1.32 % | $ 950 M | USA |
 |
NeuroMetrix
NURO
|
-8.69 M | - | 5.05 % | $ 9.02 M | USA |
 |
West Pharmaceutical Services
WST
|
756 M | $ 250.46 | -0.3 % | $ 18.1 B | USA |
 |
OraSure Technologies
OSUR
|
-17.4 M | $ 3.0 | 0.67 % | $ 223 M | USA |
 |
Pro-Dex
PDEX
|
11.9 M | $ 48.51 | 2.1 % | $ 159 M | USA |
 |
DENTSPLY SIRONA
XRAY
|
-70 M | $ 13.47 | 1.24 % | $ 2.69 B | USA |
 |
Stereotaxis
STXS
|
-21.2 M | $ 2.22 | 3.74 % | $ 179 M | USA |
 |
Milestone Scientific
MLSS
|
-6.72 M | $ 0.29 | 2.33 % | $ 23.1 M | USA |